Dr. Maura L. Gillison, a pioneering medical oncologist and molecular epidemiologist, passed away on June 21, 2026, at the age of 61. Her impactful work fundamentally altered the understanding, diagnosis, and treatment of head and neck cancers by identifying the causal role of human papillomavirus (HPV) in a significant subset of these malignancies. This discovery led to new diagnostic tests, updated staging criteria, and refined treatment guidelines, including less-intensive therapies for HPV-associated oropharyngeal cancer.
Gillison's research definitively demonstrated that HPV causes approximately 70% of oropharyngeal cancers in the U.S., a rate that has dramatically increased among adult males in recent decades. She further established that HPV status is the primary determinant of prognosis, with patients having HPV-associated oropharyngeal cancer experiencing better outcomes. Her contributions also extended to clinical trials for checkpoint inhibitors in head and neck cancer and foundational epidemiological work supporting the HPV vaccine for cancer prevention, ultimately leading to the 2020 approval of HPV vaccines for this indication.
Prior to her discoveries, head and neck cancers were solely attributed to tobacco and alcohol consumption. Her 2000 paper in the Journal of the National Cancer Institute, and subsequent major publications in The New England Journal of Medicine in 2007 and 2010, were pivotal in overturning this long-held belief. Her work also identified sexual transmission as a key risk factor for HPV-associated head and neck cancers. In recognition of her extraordinary contributions, Dr. Gillison received the David A. Karnofsky Memorial Award in 2021, ASCO's highest honor, and shared the VinFuture Grand Prize in December 2025.
